Pfizer (PFE) Competitors

$25.65
+0.25 (+0.98%)
(As of 04/29/2024 ET)

PFE vs. BMY, ZTS, ABBV, MRK, JNJ, SNY, ABT, VRTX, NVS, and REGN

Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Bristol-Myers Squibb (BMY), Zoetis (ZTS), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Sanofi (SNY), Abbott Laboratories (ABT), Vertex Pharmaceuticals (VRTX), Novartis (NVS), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "pharmaceutical preparations" industry.

Pfizer vs.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership.

Pfizer has a net margin of 3.62% compared to Pfizer's net margin of -13.50%. Bristol-Myers Squibb's return on equity of 10.88% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol-Myers Squibb-13.50% 8.83% 2.50%
Pfizer 3.62%10.88%4.91%

Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.4%. Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 6.5%. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Pfizer pays out 466.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 15 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol-Myers Squibb presently has a consensus price target of $60.00, suggesting a potential upside of 34.38%. Pfizer has a consensus price target of $36.33, suggesting a potential upside of 41.65%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts plainly believe Pfizer is more favorable than Bristol-Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol-Myers Squibb
1 Sell rating(s)
15 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.11
Pfizer
0 Sell rating(s)
10 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

Bristol-Myers Squibb has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

In the previous week, Bristol-Myers Squibb had 11 more articles in the media than Pfizer. MarketBeat recorded 81 mentions for Bristol-Myers Squibb and 70 mentions for Pfizer. Bristol-Myers Squibb's average media sentiment score of 0.48 beat Pfizer's score of 0.13 indicating that Pfizer is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol-Myers Squibb
17 Very Positive mention(s)
8 Positive mention(s)
21 Neutral mention(s)
20 Negative mention(s)
2 Very Negative mention(s)
Neutral
Pfizer
32 Very Positive mention(s)
8 Positive mention(s)
18 Neutral mention(s)
11 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pfizer received 410 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. Likewise, 69.08% of users gave Pfizer an outperform vote while only 66.87% of users gave Bristol-Myers Squibb an outperform vote.

CompanyUnderperformOutperform
Bristol-Myers SquibbOutperform Votes
1078
66.87%
Underperform Votes
534
33.13%
PfizerOutperform Votes
1488
69.08%
Underperform Votes
666
30.92%

76.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bristol-Myers Squibb has higher earnings, but lower revenue than Pfizer. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$45.01B2.01$8.03B-$3.10-14.40
Pfizer$58.50B2.48$2.12B$0.3671.25

Summary

Pfizer beats Bristol-Myers Squibb on 16 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PFE vs. The Competition

MetricPfizerPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$145.24B$6.78B$4.95B$17.45B
Dividend Yield6.61%3.09%5.36%3.55%
P/E Ratio71.2523.06239.2725.30
Price / Sales2.48326.592,463.7610.54
Price / Cash8.5317.5632.3015.39
Price / Book1.625.534.615.04
Net Income$2.12B$140.19M$101.68M$963.13M
7 Day Performance-2.55%-0.09%-0.14%0.50%
1 Month Performance-7.57%-11.00%-7.63%-3.35%
1 Year Performance-34.04%3.08%6.05%95.28%

Pfizer Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMY
Bristol-Myers Squibb
4.9409 of 5 stars
$49.00
-0.3%
$61.18
+24.8%
-33.1%$99.59B$45.01B12.6934,100Earnings Report
Analyst Revision
ZTS
Zoetis
4.9273 of 5 stars
$149.56
+2.8%
$218.00
+45.8%
-9.1%$68.40B$8.54B29.5014,100Upcoming Earnings
ABBV
AbbVie
4.8649 of 5 stars
$169.54
+1.0%
$177.43
+4.7%
+6.9%$300.20B$54.32B62.1050,000Earnings Report
Analyst Report
MRK
Merck & Co., Inc.
4.8569 of 5 stars
$126.94
flat
$131.25
+3.4%
+12.7%$321.54B$60.12B906.7172,000Earnings Report
Analyst Revision
JNJ
Johnson & Johnson
4.9353 of 5 stars
$149.56
+0.3%
$175.86
+17.6%
-10.3%$360.41B$85.16B9.32131,900
SNY
Sanofi
3.4404 of 5 stars
$47.69
+1.1%
$55.00
+15.3%
-8.5%$120.64B$46.61B20.2186,088Short Interest ↓
Analyst Revision
ABT
Abbott Laboratories
4.992 of 5 stars
$107.57
+0.5%
$121.80
+13.2%
-2.9%$186.65B$40.11B33.51114,000
VRTX
Vertex Pharmaceuticals
4.2646 of 5 stars
$404.91
+1.2%
$429.45
+6.1%
+16.3%$104.65B$9.87B29.155,400Upcoming Earnings
NVS
Novartis
3.0919 of 5 stars
$97.29
+2.3%
$114.00
+17.2%
-5.3%$198.86B$45.44B13.5576,057Gap Up
High Trading Volume
REGN
Regeneron Pharmaceuticals
4.0999 of 5 stars
$907.32
+0.8%
$976.41
+7.6%
+11.3%$98.80B$13.12B26.1113,450Upcoming Earnings

Related Companies and Tools

This page (NYSE:PFE) was last updated on 4/30/2024 by MarketBeat.com Staff

From Our Partners